SEC Form 4 · accession 0000899243-17-017408
AVEO PHARMACEUTICALS INC · AVEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael P Bailey
Officer — President & CEO · Director
Period of report
Jun 21, 2017
Accepted (ET)
Jun 28, 2017 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001325879
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.60 | Jun 21, 2017 | A | 188,666 | A | — | Feb 7, 2027 | Common Stock | 188,666 | 188,666 | D |
Explanation of responses
- F1On Febuary 8, 2017, the reporting person was granted an option to purchase 283,000 shares of common stock. Subject to the achievement of three performance milestones relating to the company's clinical trials and regulatory filings, one third of the option vests on February 8, 2018, and two thirds of the option vests on February 8, 2019. On June 21, 2017, the first two performance milestones were met. As a result, one third of the option will vest on February 8, 2018, and one third of the option will vest on February 8, 2019, in each case subject to the reporting person's continued service to the company.